Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

RCT (n=291) found primary endpoint was met with improvement in progression-free survival with venetoclax vs placebo+bortezomib+dexamethasone (22.4 vs. 11.5 months,respectively;HR 0.63;95% CI 0.44–0.90;p=0.010), but was linked to increased mortality due to increased infection rate

SPS commentary:

According to a commentary, this study paves the way for a new era of therapy in multiple myeloma: precision intervention. It suggests that oncologists will now look at cytogenetics and fluorescence in situ hybridisation in multiple myeloma through a new lens, not only as prognostic markers, but also as biomarkers for therapeutic decisions. It hopes that this will translate into therapies for other genomic alterations in multiple myeloma, which, until now, were deemed untargetable.

Source:

The Lancet Oncology

Resource links:

Commentary